. .

Medicine

( )
Involved OrganisationTypeFurther fields of acitivityFocusbased inManagementwas foundet inAddressEmailHomepageProfileContactNumber of employeesCertificatesBioChancePlusBioProfileScientific Advisory Board
DR. PETRY genmedics GMBHBiotechDevelopment, NutrigenomicsStaphylococcus researchReutlingenJustus Dehnen (CEO)
Dr. Jörg Petry (CFO)
Dr. Bernhard Krismer (CSO)
Dr. Günther Thumm (COO)
Ferdinand-Lassalle-Strasse 57
72770 Reutlingen
Germany
Tel.: +49 (0)7121-95890
Fax: +49 (0)7121-958933
info@genmedics.comwww.genmedics.comDR. PETRY genmedics GmbH focuses on research into the Staphylococcus organism. The biotechnology firm, which has bases in Reutlingen and Tübingen, is not only seeking to combat the disease pathogen but also use it as a carrier agent for various active agents.

The pathogen Staphylococcus epidermidis is capable of forming a biofilm on a range of surfaces. Thanks to its high levels of resistance to a wide range of antibiotics, pathogenic Staphylococci are becoming a major hazard in the field of medicine in the context of biofilm-related, foreign-body infections. It is for this area of activity that DR. PETRY genmedics offers an evaluation of materials for biofilm formation. As a result, new medical materials such as foreign-body implants can be checked for their biofilm formation properties.

In addition to working with pathogenic Staphylococci, the firm also focuses on the expression of therapeutically-effective proteins in the food-grade bacterium S. carnosus.
Dr. Jörg PetryOptimisation of the expression and purification of two staphylolytic active agentsAssociated project NAPRAS; Development of new agents against biofilm formation on regenerative and synthetic tissue implants; Subproject 2: Assay development, screening, verificationProf. Friedrich Götz
Prof. Günther Jung P
Prof. Joachim-Volker Höltje
Prof. Rolf G. Werner
immatics biotechnologies GmbHBiotechDevelopment, Drug DevelopmentImmune therapy, oncologyTübingenPaul G. Higham (CEO)
Dr. Carsten Reinhardt (CMO)
Dr. Harpreet Singh (CSO)
2000Paul-Ehrlich-Strasse 15
72076 Tübingen
Germany
Tel. +49 (0)7071-5651250
Fax +49 (0)7071-56512599
info@immatics.comwww.immatics.comimmatics is a biopharmaceutical company dedicated to the development of innova¬tive cancer immunotherapeutics.
immatics' proprietary technology for the identification of tumor-associated pep¬tides (TUMAPs) enables the development of novel anti-cancer vaccines for multiple cancer indications. immatics is currently developing two multi-TUMAP products in clinical phase II studies – IMA901 for the treatment of renal cell carcinoma (RCC) and IMA910 for the treatment of colorectal carcinoma (CRC). Further product candi¬dates are currently in pre-clinical de¬velopment.

With its unique proprietary XPRESIDENT™ discovery platform, immatics is constantly identifying very large numbers of naturally-presented tumor-associated peptides (TUMAPs) directly from primary tumor tissue. Since 2004 alone, the company has identified more than 50,000 TUMAP sequences and has secured the IP rights for those with high potential for use in cancer therapy.
immatics identifies TUMAPs which occur as natural ligands of HLA class I and II-receptors. These TUMAPs can activate cyto¬toxic T cells and T helper cells, key players of the cellular immune response, which have the ability to eradicate cancer cells once they are primed effectively.
TUMAPs are short peptides which are excellent drug candidates. They can be syn¬thesized and characterized by established, robust and fully scalable chemistry.		Dr. Harpreet Singh65“PROstat – regenerating micturition function in benign prostatic hyperplasia through immune therapy”
Identification, selection and validation of tumour-related peptides in stomach carcinomas aimed at defining a therapeutic vaccine based on immunogenic peptide epitopes.
Prof. Hans-Georg Rammensee
Prof. Cornelius Melief
Prof. Christoph Huber
Prof. Craig Slingluff
CureVac GmbHBiotechDevelopment, Drug Development, Trade/DistributionCureVac GmbH specialises in RNA molecules synthesised by chemical and enzymatic means. CureVac also carries out its own research in the field of tumour therapy.TübingenDr. Ingmar Hörr (CEO)
Dr. Thomas Lander (CMO)
Dr. Florian von der Mülbe (COO)
Dr. Wolfgang Klein (CFO)
Dr. Jochen Probst (CSO)		2000Paul-Ehrlich-Str. 15
72076 Tübingen
Germany
Tel: +49 (0)7071- 920530
Fax: +49 (0)7071-9205311
info@curevac.comwww.curevac.comCureVac GmbH was founded as a spin-off of the University of Tübingen and has very quickly become established as one of the leading manufacturers of nucleic acids for use as active ingredients in pharmaceutical and therapeutic applications. CureVac GmbH’s portfolio primarily includes three products. 1) Modified and non-modified short (oligo-) RNA molecules are synthesised chemically in accordance with customers’ wishes. 2) The firm also offers RNActive™, an ultra-pure and stabilised form of mRNA that enables tissue and cells to be transfixed effectively. 3) In accordance with customers’ wishes, CureVac can create cDNA libraries in copyright-protected RNActive™ vectors.Dr. Ingmar Hoerr (ih@curevac.de)48CureVac has cGMP production facilities compliant with FDA and EMEA standardsNew approach to in vivo tissue generation through RNA technology, with skin tissue as an example
TETEC® AGBiotechDevelopment, Medical Technology, Regenerative BiologyDevelopment of new methods for the treatment of complex damage to and disease of the human skeletal and locomotor system.ReutlingenDr. med. Karl-Christoph Gaissmaier
Dr. Stephan Rapp		2000Tissue Engineering Technologies -
Aktiengesellschaft zur Entwicklung und Herstellung von biologischem Gewebeersatz
Aspenhaustrasse 25
72770 Reutlingen
Germany
Tel.: +49 (0)7121-514-8760
Fax: +49 (0)7121-514-8761
info@tetec-ag.dewww.tetec-ag.deTETEC was initially founded as a limited liability company (GmbH). In 2003, TETEC® was converted into a joint-stock company (AG). “TE” stands for tissue engineering and “TEC” for innovative technologies.

TETEC AG holds a manufacturing permit in accordance with §13 Para.1 German Drug Law (AMG) for its autologous cartilage cell products NOVOCART, NOVOCART 3D and NOVOCART Disc. NOVOCART is an autologous chondrocyte preparation while NOVOCARD 3D is a combination of autologous cartilage cells and a bi-phasic, three-dimensional, collagen-based matrix. NOVOCART 3D is ideal for the biological reconstruction of articular cartilage defects. NOVOCART Disc is a high-quality, autologous cell preparation for the biological reconstruction of partially-damaged intervertebral discs following a slipped disc.

ADCT (Autologous Disc Cell Transplantation; the transplantation of in chondrocytes from autologous disc tissue that have been cultured in vitro) is the only method that facilitates the biological reconstruction of partially-damaged disc tissue before widespread degeneration occurs. The cultured cartilage cells, isolated from the biopsy material, induce the desired biological reconstruction.		Dr. Stephan Rapp20The company operates in accordance with GMP standardsTherapeutic use of adult mesenchymal stem cells (MSC) for the replacement of cartilage/bone.
Joint research project: Gelatin-based, smart biomaterials for cartilage regeneration
Gambro Dialysatoren GmbHMedtechDevelopment, Medical Technology, Trade/DistributionDialysis technologyHechingenDr. Heiko Zimmermann (CEO)1973Holger-Crafoord-Strasse 26
72379 Hechingen
Tel.: +49 (0)7471-170
Fax: +49 (0)7471-171157
info.germany@gambro.comwww.gambro.comGambro is a global group that specialises in dialysis technology, blood component technology and healthcare services. The joint-stock company, based in Sweden, is divided into Gambro Healthcare, Gambro Renal Products and Gambro BCT.

It’s Hechingen office is one of the group’s production facilities operated by Gambro Renal Products, manufacturing dialysis machines, haemoperfusion cartridges, electrolyte concentrates and other medical items for single use. Hechingen is also home to the research and development centre for dialysis machines/membrane technology and the logistics and distribution centre for Germany, Switzerland, Austria and the Benelux countries.

One of the branch offices of Gambro Dialysatoren GmbH, which is also located in Hechingen, solely produces catheters for use in dialysis.		Approx. 1500CE certificate as per EC guideline 93/42EEC, certificate compliant with ISO 13485, Certificate ISO 14001, basic certificate from the “Beruf + Familie” auditNew, molecularly-defined, MIF-based methods for extracorporal apheresis aimed at regenerating plasma in sepsis and SIRS.
Antibacterial and biofunctional surfaces for extracorporal and cell therapy methods.
Mediagnost GmbHBiotechDevelopment, Nutrigenomics, DiagnosticsTesting systems for numerous applications in the field of infection diagnosis, endocrinology and food analysis; the production of antibodies, proteins and virusesReutlingenDr. Angelika Haage (Managing Director)1985Aspenhaustrasse 25
72770 Reutlingen
Germany
Tel.: +49 (0)7121-51484-0
Fax: +49 (0)7121-51484-10
info@mediagnost.dewww.mediagnost.deMediagnost GmbH was founded in 1985 in Tübingen and is now based in the Tübingen-Reutlingen technology park.

Mediagnost produces antibodies, proteins and viruses in accordance with GMT guidelines. The testing systems focus on infectious diseases such as hepatitis A/C, enteroviruses, HIV and the diagnosis of Pseudomonas aeruginosa. The firm’s portfolio also includes testing systems for the qualitative demonstration of genetically-modified foods and contamination of food, along with immunoassays used in endocrinology. 		Dr. Angelika Haage Production in accordance with GLP and GMP guidelines as decreed by the German Drug Law (AMG) and the Act on Medical Devices (MPG). Quality management system certified according to ISO 9001:2000.AgeQuant – development of a multi-dimensional testing system for the quantitative determination of parameters relevant to regenerative biology in ageing humans.

JOTEC GmbHMedtechDevelopment, Medical Technology, Process EngineeringDevelopment and production of vessel prostheses and stenting systemsHechingenThomas Bogenschütz, CEO
2000Lotzenäcker 23
72379 Hechingen
Germany
Tel.: +49 (0)7471-9220
Fax: +49 (0)7471-922100
info@jotec.netwww.jotec.netSince 2000, the medical technology firm has been developing and producing various systems that can be used to treat vascular diseases. Its portfolio of products includes vessel prostheses made from ePTFE and polyester. Coating technologies involving collagen and heparin reduce the risk of thrombosis.

The firm also supplies stents, stent prostheses and various insertion systems that are designed based on its experience of nitinol and catheter technologies.

In the field of tissue engineering, JOTEC offers a patch made from a micro-porous collagen matrix and collagen membrane (Matricart) that helps in the creation of autologous cartilage implants.		125In vivo endothelialisation of vessel prostheses through coating with DNA aptameres as catcher molecules for endothelial progenitor cells (EPC).


PANATecs GmbHBiotechServices, Development, Nutrigenomics, DiagnosticsProvision of bioanalytical services, particularly mass spectrometry-based, for the pharmaceutical, foodstuffs and animal feed industries. Manufacture and sale of bioanalytical substances for research (e.g. peptides, antibodies, marker reagents etc.).TübingenDr. Thomas Flad, Pharmacist (CSO)
Alexander Cansier (COO)
2004Ob dem Himmelreich 7
72074 Tübingen
Germany
Tel.: +49 (0)7071-29720-93, -94 and -95
Fax: + 49 (0)7071-294445
info@panatecs.comwww.panatecs.comPANATecs GmbH was founded in 2004 as a spin-off of the University of Tübingen. Its founding partners are Prof. Claudia Müller (Transplantation Immunology and Immunohaematology Section, “Medizinische Klinik und Poliklinik”, Dept. II), Prof. Gerhard A. Müller (Nephrology & Rheumatology Department, Centre for Internal Medicine, Georg August University, Göttingen), Dr. Hubert Kalbacher (University of Tübingen, Physiological Chemistry Institute (PCI), Medical and Scientific Research Centre, University of Tübingen) and the two Managing Directors Dr. Thomas Flad and Alexander Cansier.

In addition to the production of bioanalytical products and the conducting of specialist analyses, PANATecs GmbH also carries out its own research projects. In collaboration with major partners, the firm handles projects from the field of clinical mass spectrometry. The aim of these research activities is to develop new, mass spectrometry-based diagnostic methods for the early detection of autoimmune and cancer-related diseases.
Alexander Cansier12Development of new tests for the molecular diagnosis of rheumatoid arthritis
CenTrial GmbHBiotechServicesContract research, CRO, services in clinical studies, trainingTübingenProfessor Christoph H. Gleiter (CEO)
Dr. Armin Bauer (Project Manager)
2000Otfried-Müller-Strasse 45
72076 Tübingen
Germany
Tel.: +49 (0)7071-2972262
Fax: +49 (0)7071-295158
sekretariat.kks@kks-tu.dewww.kks-tu.deCenTrial, a joint venture by the University Hospitals of Tübingen and Ulm, offers support in a CRO role in cooperation with study managers from the hospital, clinical practices, contract research institutes and industry in accordance with national and international standards. The studies are carried out to high levels of clinical, statistical methodological, technical and ethical quality, and are of high calibre with regard to health economics.
CenTrial welcomes all studies and works with departments at the University Hospitals of Tübingen and Ulm, other study centres, affiliated physicians and industry partners. Through this network, CenTrial can provide a full spectrum of services, either individually or as all-in-one solutions.
CenTrial was founded in December 2000 as an affiliated company of the University Hospital of Tübingen. Since 1 January 2006, CenTrial has been an affiliated company of the University Hospitals of Tübingen and Ulm.
Professor Christoph H. Gleiter40Quality management system/certification to DIN EN ISO 9001:2000
Quality assurance in accordance with ICH-GCP
Fraunhofer-Institut für Grenzflächen- und Bioverfahrenstechnik IGBInstituteServices, Development, Chemistry, Process EngineeringThe creation of solutions for business and public clients in the fields of health, the environment and technologyStuttgartProf. Dr. Thomas Hirth (Institute Director)1952Nobelstrasse 12
70569 Stuttgart
Germany
Tel.: +49 (0)711-9704001
Fax: +49 (0)711-9704200
info@igb.fraunhofer.dewww.igb.fraunhofer.deIGB’s roots go back to 1952, the year in which the Institute of Surface Physics and Chemistry was founded. The Institute was taken over in 1962 by the Fraunhofer Society. The Institute was given its present name in 1976, coinciding with the creation of the research fields involving bioprocess technology and membrane technology.

The Fraunhofer IGB is one of six Fraunhofer institutes in Stuttgart, the Fraunhofer Society’s largest location.

The IGB’s main areas of expertise include surface technology, membrane technology, biotechnology, cell system technology and bioprocess technology. The IGB offers its clients full-service solutions, ranging from market analysis and research to ready-to-use development.

The scientists working at the IGB focus on various disciplines – from physics, chemistry, biology and molecular biology to engineering-related sciences. Their goal is to translate biological and biochemical problems and challenges in product preparation and environmental technology into commercially-attractive and environmentally-friendly processes and products.

The IGB’s core areas of research are handled in four divisions, each focusing on different areas of application or business. 1) The “Molecular Substances for Pharmaceuticals and Chemical Industries” division focuses primarily on the development of therapeutic proteins and target screening, diagnostic methods using biochips and diagnostic agents, biocatalysis and enzyme screening, fermentation, downstream processing and scale-up production.

The second division focuses on the development of 3-dimensional, organoid cell structures as test systems, tissue engineering and manufacturing based on GMP guidelines. In the “Functional Surfaces and Membranes” division, the scientists primarily work on surface-dominated polymers, biomaterials and biomimetic surfaces, together with the design of new membranes. The Fraunhofer IGB’s fourth division is devoted to biotechnical environmental rehabilitation, the recycling of organic waste, waste water purification and water management and the regenerative production of materials using microalgae.

In addition to this purely R&D-based activity, the Fraunhofer IGB also offers services in various sectors such as analysis, molecular biology, cell biology and commissioned research into cell therapy agents based on GMP.		Dr. Claudia Vorbeck (claudia.vorbeck@igb.fraunhofer.de)140Accreditation to DIN EN ISO/IEC 17025 for HPCL, IC, GPC, GC and GC/MS, ESCA; GMP unit and manufacturing permit for autologous chondrocyte transplants (others have been applied for).
heckel medizintechnik GmbHMedtechMedical Technology, Trade/DistributionDevelopment, manufacture and sale of systems for full-body and local hyperthermiaEsslingenStefan Heckel-Reusser (Management)1994Blumenstrasse 18
73728 Esslingen
Germany
Tel.: +49 (0)711-9315891
Fax: +49 (0)711-9315893
info@heckel-medizintechnik.dewww.heckel-medizintechnik.deheckel medizintechnik gmbh was founded at the end of 1994 under the name “heckel – Therapeutic Infra-Red Systems”. The firm develops, produces and sells full-body hyperthermia systems that artificially raise the body temperature using infra-red radiation, thereby stimulating the body’s self-healing abilities in people with chronic illness. These systems, which feature a newly-developed, multi-functional reflection tent, are used to treat various conditions including degenerative diseases of the musculoskeletal system, chronic inflammatory diseases and cancer-related illnesses.

The company sells equipment for local deep hyperthermia which is used in the treatment of tumours.		Stefan Heckel-Reusser3All products bear the CE mark and comply with the requirements of the European medical products guideline 93/42/EEC. Certified according to EN ISO 13485 and EN ISO 9001 by the TÜV Product Service, Munich.
EC certificate for the quality assurance system in place in its hyperthermia equipment division and physiological monitoring systems (as per Appendix II, MDD 93/42/EEC).


biosyn Arzneimittel GmbHBiotechDevelopment, Drug Development, Nutrigenomics, Diagnosticsbiosyn Arzneimittel GmbH was founded 1984 and is one of the first biotechnology companies. As a research oriented company biosyn focuses on oncology and intensiv care medicine.FellbachDr. Thomas Stiefel (Managing Director)
Ortwin Kottwitz (Managing Director)
1984Schorndorfer Strasse 32
70734 Fellbach
Germany
Tel: +49 (0)711-5753200
Fax: +49 (0)711-5753299
info@biosyn.dewww.biosyn.debiosyn Arzneimittel GmbH has specialised primarily in the fields of oncology and intensive care medicine biosyn currently offers around 30 drugs approved in 15 countries.
biosyn's develpoment strategy is based on biologic molecules and trace elements that have proven efficacy with few side effects. Hemocanin based products like IMMUCOTHEL® or VACMUNE® are used in bladder cancer or as carriers for therapeutic vaccines. Selenium compounds like Sodiumselenite (selenase®) are used in sepsis patients to reduce mortality.

In a double-blind, prospective study (SIC) study it could be demonstrated that high dose sodium selenite reduces the mortality rate for sepsis patients. The mortality rate among patients who were administered the drug was 42% as opposed to 57% for the control group. High dose selenium leads to a significant reduction (14,3%) in the mortality rate even in cases of severe sepsis such as septic shock.

biosyn Vertriebs AG in Balzers, Liechtenstein and the biosyn Corporation in Carlsbad, California, USA, are subsidiaries of biosyn. biosyn also has a scientific office in Austria.		Approx. 80biosyn’s laboratories in Fellbach are GMP-certified
ERBE Elektromedizin GmbHMedtechDevelopment, Medical Technology, Trade/Distribution, Process EngineeringDevelopment, manufacturing and sale of systems for electrosurgery, cryosurgery and physiotherapy. TübingenChristian O. Erbe (CEO)
Reiner Thede (CEO)
1847Waldhörnlestrasse 17
72072 Tübingen
Germany
Tel.: +49 (0)7071-7550
Fax: +49 (0)7071-755179
sales@erbe-med.dewww.erbe-med.deERBE Elektromedizin GmbH was formed from the workshop founded by Christian Heinrich Erbe in Tübingen 1847.

ERBE develops and produces systems for electro-, cryo- and ophthalmological surgery and physiotherapy. It also markets a water jet-based surgery system. Its portfolio is geared towards surgical installations in all manner of disciplines within hospitals and specialist physicians’ practices both within Germany and abroad.

The company has subsidiaries across Europe and in the USA, representatives in China and Russia and trade agencies worldwide.
500 (worldwide), 400 (Germany), 350 (Tübingen)QM system: ISO 9001, ISO 13485
Appendix II of Guideline 93/42/EEC;
Licences: Conformity assessments and permits as decreed by EC guideline 93/42/EEC
AnDiaTec GmbH & Co. KGMedtechDevelopment, Medical Technology, DiagnosticsInnovative in vitro diagnostics for human and veterinary medicine, together with the food and environmental sectorKornwestheimDr. Johannes Kehle (CEO)
2003Leibnizstr. 11
70806 Kornwestheim
Germany
Tel.: +49 (0)7154-806 23-0
Fax: ++49 (0)7154-806 23-24
info@andiatec.comwww.andiatec.comAnDiaTec was founded by Dr. Johannes Kehle and Dr. Christoph Metzger-Boddien.

AnDiaTec GmbH & Co. KG’s core activities focus on the development, manufacture and sale of in vitro diagnostic tools.

The products marketed include ParaTub® and LactoScan®. ParaTub® is currently the only high-throughput detection method for Mycobacterium paratuberculosis (MAP), the pathogen responsible for incurable paratuberculosis in cattle. MAP causes major economic damage and is also linked to the inflammatory bowel condition called Crohn’s disease in humans.

LactoScan® is a simple and rapid test for reliably detecting lactose intolerance in humans. It is likely that more than 10 million people in Germany are affected by lactose intolerance, a disease that, in the form of primary lactose intolerance, has genetic causes and can lead to under-supplies of lactase between the ages of 6 and 20 and subsequently lead to symptoms typical of the disease.

AnDiaTec GmbH & Co. KG is also an adviser to the WHO in the context of a diagnostic project for enteroviruses in India.		The laboratory is accredited in accordance with DIN EN ISO IEC 17025 and 15189
npi electronic GmbHBiotechDevelopment, Drug Development, Laboratory Techniques, Process EngineeringElectronic measuring instruments for the life sciences sector, drug-screening systemsTammHannelore Polder
Hans Reiner Polder (M.Sc.EE)
1989Hauptstrasse 96
71732 Tamm
Germany
Tel.: +49(0)7141-9730230
Fax: +49(0)7141-9730240
sales@npielectronic.comwww.npielectronic.comHans Reiner Polder founded npi in 1989 based on the method he developed to improve the measurement of intracellular signals. Using this newly-developed enhancement system, it was possible to improve the resolution capabilities of existing measuring systems. npi currently has a wide portfolio of products for recording bio-electrical signals. npi develops and sells numerous systems for use in fundamental medical, biological and drug research, such as voltage and patch clamp amplifiers, intra- and extracellular amplifiers, micromanipulators etc. The firm also offers products for drug screening and laboratory automation. npi electronic is a member of the Electrophysiology Innovation Partnership network. Hans Reiner Polder5
Synovo GmbHBiotechServices, Development, Drug DevelopmentTesting methods for choosing drug candidatesTübingenDr. Michael Burnet (CEO)Paul-Ehrlich-Strasse 15
72076 Tübingen
Germany
Tel.: +49 (0)7071-964325
Fax +49 (0)7071-964326
contact@synovo.comwww.synovo.comSynovo GmbH is a pharmaceutical research company that offers services in the fields of synthetic chemistry, pharmacology, cell engineering and peptide modification.

The company’s focus lies in providing various testing methods and models – ideally using human cells, proteins or systems – for the selection of drug candidates with improved properties in terms of absorption, distribution, metabolism and elimination (ADME or DMPK). On behalf of customers from the pharmaceutical industry, Synovo is involved in projects investigating anti-inflammatory and immuno-suppressive drug optimisation and the improvement of existing technologies used for the development of new drugs from proteins and nucleic acids. This work is carried out in collaboration with public-sector laboratories.
Dr. Michael Burnet 20
Translumina GmbHMedtechDevelopment, Medical Technology, Process EngineeringInternational company for medical technology focussing on drug-eluting stent systems
HechingenLars Sunnanväder (Managing Director)2000Marketing & Sales
Steinsdorfstraße 8
80538 München
Germany
Tel.: +49 (0)89-210289-0
Fax: +49 (0)89-210289-29
Production
Neue Rottenburger Straße 50
72379 Hechingen
Germany
Tel.: +49 (0)7471-9894-0
Fax: +49 (0)7471-9894-380
info@translumina.dewww.translumina.deTranslumina GmbH was established in 2000 and since then has developed into a leading company in the production and development of innovative and biocompatible stent coatings.

Translumina has developed a coating system (YUKON®DES Drug Eluting Stent) and the Stent Coating Machine (SCM) for cardiac stents (vessel wall supports), which allow doctors to apply a customised medication coating to a stent, which is then inserted into the coronary vessels. The coating prevents occlusion and restenosis of the vessel. The active substance can be applied to the stent without the need for additional polymers. 		40
University Hospital of TübingenInstituteEducationCentre for healthcare, science and educationTübingenProf. Dr. med. Michael Bamberg, Managing Medical Director and Chairman of the Executive Board of Directors
Rüdiger Strehl, Commercial Director and Deputy Chairman of the Executive Board of Directors
Gabriele Sonntag, Commercial Director and Deputy Chairwoman of the Executive Board of Directors
Prof. Dr. med. Karl-Ulrich Bartz-Schmidt, Deputy Managing Medical Director
Prof. Dr. med. Ingo B. Autenrieth, Dean of the Medical Faculty
Günther Brenzel, Director of Nursing		1805Geissweg 3
D-72076 Tübingen
Tel. +49 (0)7071 - 290
Fax +49 (0)7071 - 29-39 66
vorstand@med.uni-tuebingen.dewww.medizin.uni-tuebingen.deThe University Hospital of Tübingen has established itself as a leading centre of German university medicine. The German Science Council has attested the Hospital and the Medical School’s outstanding achievements in research, education and healthcare as well as its role as a pacemaker for university medicine in Germany.
As a hospital offering maximum medical care and with a catchment area extending from the Mittlerer Neckar metropolitan region to Lake Constance, Tübingen University Hospital is known beyond its regional borders and functions as a district hospital for the city and district of Tübingen. Since January 1998, the Hospital has been a public-law institution with a board of directors and a supervisory board. 		ca. 8500
flyion GmbHBiotechDrug Development, Trade/Distribution, Laboratory TechniquesAutomated patch clamp technologyTübingenPD Dr. Albrecht Lepple-Wienhues (CEO)
Dr. Dirck Lassen (Vice President of Commercial Operations)
2001Waldhäuserstrasse 64
72076 Tübingen
Germany
Tel.: +49 (0)7071-688830
Fax: +49 (0)7071-6888399
info@flyion.comwww.flyion.comflyion GmbH was founded by Dr. Albrecht Lepple-Wienhues and Dr. Klaus Ferlinz in 2001 as a spin-off of the University of Tübingen (Institute of Physiology). The founders were supported by i.con.innovation.

In 1991, Erwin Neher and Bert Sakmann won the Nobel Prize in Medicine for their groundbreaking study of ion channels. In its conventional form, the patch clamp process that they developed is extremely labour intensive and demands a high degree of manual dexterity in order to yield reliable results. flyion has simplified this procedure with its patented Flip-the-Tip™ technology, which is ideally suited for automation.

The company offers a range of products based on this technology:
· The Flyscreen® 8500 is a patch clamp robot that performs high-quality ion channel screenings automatically. Several compounds can be tested one after the other.
· The PatchBox™ is a cost-effective plug&play workstation tool that can be combined with existing amplifiers, pullers and software. It is simple to operate and delivers a high success rate in the automatic formation of gigaseals and whole-cell configurations in a standard patch pipette.
· The ChipTip™ recording tips for the Flyscreen® 8500 consist of a glass pipette in a plastic casing. They ensure high success rates and allow extremely fast solution exchange within the pipette while keeping volumes to an absolute minimum for the study of the fastest ligand-dependent ion channels.
· The Feedback Microforge is a fully automatic micro glass pressure polishing system for the production of special glass pipette shapes in patch clamp technology.

As a solutions provider, and to complement its product range, flyion also offers the following services that help ensure the company’s products are used efficiently:
· hERG safety analysis of active substances
· Ion channel screening to help discover new active substance candidates
· Creation and characterisation of stably transfixed, inducible cell lines
· Optimisation of assays for automated ion channel screenings

Ulrike Jakl for general queries (info@flyon.com)
GlaxoSmithKline Consumer Healthcare GmbH & Co. KGBiotechNutrigenomics, Trade/DistributionOral care/dental health, pharmacy-only and freely available medicines/dietary supplementsHerrenbergManaging Directors:
Jürgen Reinhardt
Adrian Bauer
Klaus Seeger
Herman van Barneveld
Cornelis van Schagen 		Headquarters:
Bußmatten 1
77815 Bühl/Baden
Germany
Tel.: +49 (0)7223-76-0
Fax: + 49 (0)7223-76-4000
Production/R&D location:
Benzstr. 25
71083 Herrenberg
Germany
Tel.: +49 (0)7032-9220
Fax: + 49 (0)7032-5221
unternehmen@gsk-consumer.dewww.gsk-consumer.deGlaxoSmithKline is one of the world’s leading healthcare companies. 100,000 people throughout the world work in the areas of pharmaceuticals (prescription medicines/vaccines) and consumer healthcare (products for oral and dental health and self medication). GlaxoSmithKline is represented in Germany by its Pharmaceuticals division based in Munich and its Consumer Healthcare division headquartered in Bühl. The Consumer Healthcare location in Bühl is responsible for business in Germany, Austria and Switzerland. The Herrenberg site is home to R&D for vitamin supplements and natural remedies, as well as being the production site for natural remedies and oral care products such as Odol® mouthwash.

Odol®, Odol-med3®, Dr. Best®, Sensodyne®, Chlorhexamed® and Corega® are helping to improve dental health and are market leaders in the oral hygiene markets. Abtei is the largest brand in the freely available medicines/dietary supplements sector. The vitamin supplements Cetebe® and Eunova®, the plant-based urological product Granu Fink®, NiQuitin® (to help stop smoking), Zovirax® (to treat cold sores) and Formigran® (to treat migraines) represent key areas of expertise in the market for self-medication products available only from pharmacies (pharmacy-only products).

With around 560 employees and innovative healthcare concepts represented by strong brands, GlaxoSmithKline Consumer Healthcare is one of the most successful companies in the sectors of oral care/dental health and both freely available and pharmacy-only medicines/dietary supplements.
Ms. Ulli Manz/Company Communication; Tel.: + 49 (0)7223-76-2221; Fax: + 49 (0)7223-76-3221
The Microarray FacilityBiotechServices, DiagnosticsAnalyses with DNA chipsTübingenDr. Michael Bonin (CEO)2001Medizinische Genetik
Calwerstrasse 7
72076 Tübingen
Germany
Tel.: +49 (0)7071-2972295
Fax: +49 (0)7071-295172
michael.bonin@microarray-facility.comwww.microarray-facility.comThe Microarray Facility at the University of Tübingen specialises most notably in providing services based on Affymetrix GeneChip® technology.
Microarrays have a versatile range of diagnostic uses. The Microarray Facility diagnostic tools include the Roche AmpliChip which has been approved by the US FDA as a tool for in vitro diagnosis to examine 33 different alleles of the cytochrome P450 enzymes 2D6 and 2C19. Doctors can then use the result to adjust the individual dose of drugs where the two enzymes are involved. The Affymetrix CustomSeq® resequencing array, which enables analysis of the CFTR gene, can be used to help diagnose cystic fibrosis, a commonly autosomal recessive hereditary disorder. Oligonucleotide arrays have a number of applications, including genetic coupling or association studies and the detection of chromosomal defects.
Casualty Hospital TübingenInstituteRegenerative BiologyClinic and research focusing on trauma surgeryTübingenProf. Dr. med. K. Weise (Medical Director)
P. Mast (Financial Officer)
Doris Dietmann (Director of Care)

Responsible Body
Verein für Berufsgenossenschaftliche
Heilbehandlung Heidelberg e.V.
Kurfürsten-Anlage 62
69115 Heidelberg
Dr. E. Radek (Managing Director)		Schnarrenbergstr. 95
D-72076 Tübingen
Tel.: +49 (0)7071-6060
info@bgu-tuebingen.dewww.bgu-tuebingen.deThe Casualty Hospital in Tübingen is one of the best-known clinics in Germany for trauma and reconstructive surgery. It has a state-of-the-art centre for the surgical treatment of a broad range of injuries, including polytrauma and the treatment of severe burns. Besides trauma and reconstructive surgery, as well as plastic, hand and tumour surgery, the Casualty Hospital Tübingen specialises in the treatment of spinal cord injuries, knee and hip joint endoprostheses, orthopaedic rehabilitation, intensive care medicine and pain therapy. Since February 2006, the Clinic for Oral and Maxillofacial Surgery has also been part of the Casualty Hospital Tübingen.

The clinic treats over 8,500 inpatients per year and around 25,000 outpatients. Its teams of surgeons carry out approximately 34,000 surgical interventions per year. The clinic is open to people who have suffered accidents at work as well as panel patients and private patients.

The clinic is run by the “Verein für Berufsgenossenschaftliche Heilbehandlung Heidelberg e.V.“ association which is part of BG Chemie (Employers' Public Liability Insurance Association in Germany, Berufsgenossenschaft der chemischen Industrie) located in Heidelberg.

The clinic works closely with the University of Tübingen and is in charge of activities related to trauma, hand, plastic and burn surgery in patient treatment, research and education.
In the area of research, the Casualty Hospital Tübingen mainly focuses on autologous cartilage transplantation (ACT), and some of the insights gained have already been incorporated in clinical applications. In close cooperation with the NMI – Natural and Medical Sciences Institute at the University of Tübingen, the clinic is working on improving ACT, with the goal of being able to treat degenerative cartilage diseases.
Graduate School of Cellular & Molecular NeuroscienceInstituteEducationGraduate education in the neurosciencesTübingenProf. Dr. Horst Herbert (Coordinator)University of Tübingen
Graduate Training Centre of Neuroscience
Österbergstraße 3
D-72074 Tübingen
Tel.: +49 (0)7071-2977179
Fax: +49 (0)7071-295089
neuro.office@uni-tuebingen.dewww.neuroschool-tuebingen-molec.deThe Graduate School of Cellular & Molecular Neuroscience was established at the University of Tübingen in 2007 through the joint efforts of the Medical School, the School of Biology and the School of Biochemistry & Pharmacy. It is strongly supported by the Hertie Institute for Clinical Brain Research, the Tübingen Centre of Neurodegenerative Diseases, the Centre for Integrative Neurosciences and the NMI Natural and Medical Sciences Institute at the University of Tübingen.

The programme gives students (master/PhD) an interdisciplinary education in the neurosciences, with particular focus on the practical and theoretical training in the molecular and cellular biology of neurodegenerative diseases, mechanistic aspects of neural plasticity and neuroregeneration, basic mechanisms of learning and memory and modern microscopy methods.

International students receive financial support (grants) from the programme’s cooperation partners, the Hertie Foundation and the Helmholtz Society. The Graduate School of Cellular & Molecular Neuroscience works closely with the Graduate School of Neural & Behavioural Sciences.
Graduate School of Neural & Behavioural Sciences - International Max Planck Research SchoolInstituteEducationGraduate education in the neurosciencesTübingenProf. Dr. Horst Herbert (Coordinator)University of Tübingen
Graduate Training Centre of Neuroscience
Österbergstraße 3
D-72074 Tübingen
Tel.: +49 (0)7071-2977179
Fax: +49 (0)7071-295089
neuro.office@uni-tuebingen.dewww.neuroschool-tuebingen-cogni.deThe Graduate School of Neural & Behavioural Sciences – International Max Planck Research School was established at the University of Tübingen in 1999 through the joint efforts of the Medical School, the School of Biology and the Max Planck Institute for Biological Cybernetics. Additional training is provided by the Hertie Institute for Clinical Brain Research, the Centre for Integrative Neuroscience and the NMI Natural and Medical Sciences Institute at the University of Tübingen.

Graduate students begin with a one-year interdisciplinary practical and theory-based training period, followed by a master’s and subsequently a doctoral thesis. The main training focus is sensory and motor systems neuroscience, neuropsychology, neurophysiology and specific brain imaging methods, both with regard to the healthy and the diseased brain.

International students receive financial support from the Max Planck Society in the form of grants. The Graduate School of Neural & Behavioural Sciences works closely with the Graduate School of Cellular & Molecular Neuroscience.
International Reference Centre DNA VirusesInstituteDevelopment, GenomicsInternational reference centre for the genomics and diagnosis of viruses with small circular DNAStuttgartProf. Dr. Holger JeskeUniversität Stuttgart
Biologisches Institut
Pfaffenwaldring 57
D-70550 Stuttgart
Tel. +49 (0)711-68565070
holger.jeske@bio.uni-stuttgart.dewww.uni-stuttgart.deResearchers at the University of Stuttgart, in cooperation with two academic groups led by Prof. Dr. Eduardo Rodríguez Bejarano, Universidad de Malaga, and Dr. Bruno Gronenborn, Institut des Sciences du Végétal, Paris along with the company Qiagen as industrial partner and specialist in diagnostic test methods, have been operating an international virus reference centre since 2007. The centre receives a total of 1.2 million euros in funding from the EU for a period of three years, of which 600,000 euros go towards the research carried out by the Stuttgart researchers.

A major focus of the centre is the establishment of a gene bank to store and characterise viral DNA from across the globe. The Stuttgart scientists are specifically focusing on Gemini viruses with a two-component genome, the Spanish scientists are working on Gemini viruses with a one-component genome and the French scientists are researching nanoviruses. All these viruses are known to cause numerous plant diseases.
Southwest German Tumour Centre - Comprehensive Cancer Centre TübingenInstituteDiagnosticsDiagnostics, therapy and cancer research TübingenProf. Dr. Diethelm Wallwiener (Director)Herrenberger Str. 23
D-72070 Tübingen
Tel.: +49 (0)7071-2985235
tumorzentrum@med.uni-tuebingen.dewww.ccc-tuebingen.de, www.tumorzentrum-tuebingen.deThe mission of the Southwest German Tumour Centre - Comprehensive Cancer Centre Tübingen (CCC) is to focus on cancer research, promote multiprofessional cooperation and ensure optimal care for cancer patients. The Centre is well aware of the fact that the diagnosis and therapy of the 200 or more known tumours requires the cooperation of specialists of numerous disciplines. As one of five top oncology centres in Germany, the CCC has been funded by German Cancer Aid since March 2007.
Cancer specialists from the University of Tübingen work in interdisciplinary tumour-specific centres within the CCC. Experienced diagnosticians, surgeons, internal medicine specialists and radiotherapists hold 16 tumour conferences per week with the aim of finding the best possible therapy for individual patients. The Tumour Centre stands out for its close integration of patient care and research, which enables the rapid transfer of research results into clinical practice.
Centre for Clinical Transfusion Medicine Tübingen gGmbHInstituteDiagnosticsSupply of patients with blood products and immunohaematological diagnosticsTübingenProf. Dr. Hinnak Northoff (Medical Director)Otfried-Müller-Str. 4/1
D-72076 Tübingen
Tel.: +49(0)7071-2981616
www.blutspendezentrale.deThe Centre for Clinical Transfusion Medicine Tübingen gGmbH (ZKT) is a joint venture of the Baden-Württemberg – Hesse DRK blood donation service and the University Hospital of Tübingen.

The Centre for Clinical Transfusion Medicine supplies patients in all the clinics at Tübingen University Hospital and a number of other hospitals in the region with blood products. The vast majority of blood products required can be covered with donations obtained by the Blood Donation Centre in Tübingen. In addition, the ZKT is in charge of immunohaematological diagnostics.

The ZKT has clean rooms where work is carried out according to international GMP (Good Manufacturing Practice) standards.
Ocuserv GmbHBiotechServicesOpthamology servicesTübingenJasminweg 23
72076 Tübingen
Germany
Tel.: +49 (0)7071-650513
Fax: +49 (0)7071-650515
office@ocuserv.dewww.ocuserv.deThe company offers a range of services based on its expertise in clinical and scientific opthamology. Its service portfolio ranges from organising courses and conferences, coordinating research projects, developing databases, preparing scientific reports and other documentation, researching and developing processes and equipment right through to ophthalmological diagnostics and treatment.
Paul-Lechler Hospital and Clinic for Tropical DiseasesInstituteClinic for tropical medicine, geriatrics and pain treatmentTübingenDr. Gisela Schneider (Director)Paul-Lechler-Str. 24
72076 Tübingen
Tel.: +49 (0)7071-2060
info@tropenklinik.dewww.tropenklinik.deThe Paul-Lechler Hospital and Clinic for Tropical Diseases specialises in tropical and travel medicine, microbiology and the epidemiology of infections. The tropical disease department treats around 2500 patients annually.

Over the last few years, the Hospital has also established General Internal Medicine, Palliative Medicine and Diabetology departments. The most frequent reason for visiting the hospital is for the treatment of internal diseases. The Paul-Lechler Hospital and Clinic for Tropical Diseases is part of the Centre of Geriatrics at the University of Tübingen.

For many years, pain therapy has been another major treatment priority at the Hospital. In cooperation with the Tübingen project “Häusliche Betreuung Schwerkranker” (Home care of critically ill people), the Hospital’s palliative medicine department is a role model for treatment centres of its kind in the region.

The Hospital was established in 1916 and was initially a medical treatment and convalescent centre for sick missionaries.
Hertie Institute for Clinical Brain Research (HIH)InstituteResearch into the brain and brain diseases (in particular Alzheimer’s, Parkinson’s)TübingenProf. Dr. Thomas Gasser
Prof. Mathias Jucker
Prof. Dr. Arthur Melms
Prof. Hans-Peter Thier

Wolfgang Pfaff (Managing Director)		Otfried-Müller-Str. 27
72076 Tübingen
www.hih-tuebingen.deThe Hertie Institute for Clinical Brain Research (HIH) was established in 2002 by the University of Tübingen and the non-profit Hertie Foundation in Frankfurt. The Institute combines neuroscientific research with the clinical treatment of brain disorders. The Institute is located in a research building on the Schnarrenberg campus in Tübingen.

The HIH has four divisions:
General Neurology (Interim Director: Prof. Arthur Melms)
Cognitive Neurology (Director: Prof. Hans-Peter Thier)
Neurodegenerative Diseases (Director: Prof. Thomas Gasser)
Cell biology of neurological diseases (Director: Prof. Mathias Jucker)

The HIH employs around 200 scientists under the leadership of 10 renowned professors, who investigate the information-theoretical and neuronal basics of important brain functions such as perception, memory and learning. These findings are used to prevent and treat brain diseases such as Alzheimer’s, Parkinson’s, stroke, tumours or multiple sclerosis. In addition, the scientists analyse brain-oriented applications for technological applications, for example traffic safety systems.

The Hertie Institute for Clinical Brain Research has close structural connections with the Hospital for Neurology, both of which are part of the Centre of Neurology, a multifunctional institution which is able to offer clinical brain research, medical treatment and scientific education.